Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

  • 1 October 1998
    • journal article
    • review article
    • p. S277-89
Abstract
A new generation of "bivalent" gp120-based vaccines, effective against subtype B and subtype E viruses, has been developed. Antisera from rabbits and humans immunized with these vaccines are able to neutralize macrophage tropic and T-cell tropic viruses grown in activated peripheral blood mononuclear cells (PBMCs). These vaccines are now available for efficacy trials to determine the role of humoral immunity in providing protection against human immunodeficiency virus type 1 (HIV-1) infection.

This publication has 0 references indexed in Scilit: